Traders Buy Shares of Thermo Fisher Scientific Inc. (TMO) on Weakness
Investors bought shares of Thermo Fisher Scientific Inc. (NYSE:TMO) on weakness during trading on Thursday. $74.43 million flowed into the stock on the tick-up and $53.69 million flowed out of the stock on the tick-down, for a money net flow of $20.74 million into the stock. Of all companies tracked, Thermo Fisher Scientific had the 18th highest net in-flow for the day. Thermo Fisher Scientific traded down ($0.08) for the day and closed at $158.82
A number of equities analysts have recently commented on TMO shares. Mizuho lifted their price target on shares of Thermo Fisher Scientific from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, April 4th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $164.00 price target on the stock in a research report on Tuesday, May 3rd. Morgan Stanley restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Saturday, April 30th. Leerink Swann restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Saturday, April 30th. Finally, Bank of America Corp. restated a “buy” rating and issued a $163.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $157.54.
The firm has a market capitalization of $62.50 billion and a price-to-earnings ratio of 31.96. The stock’s 50-day moving average price is $151.68 and its 200-day moving average price is $143.02.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.02. The business earned $4.54 billion during the quarter, compared to the consensus estimate of $4.50 billion. During the same quarter last year, the company posted $1.84 EPS. The firm’s revenue was up 6.2% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post $8.13 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Thursday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date of this dividend is Tuesday, September 13th.
In other Thermo Fisher Scientific news, VP Peter M. Wilver sold 68,200 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $152.38, for a total transaction of $10,392,316.00. Following the transaction, the vice president now owns 64,727 shares in the company, valued at approximately $9,863,100.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas W. Loewald sold 15,000 shares of the stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $152.84, for a total value of $2,292,600.00. Following the transaction, the senior vice president now owns 49,169 shares in the company, valued at approximately $7,514,989.96. The disclosure for this sale can be found here.
Other hedge funds and institutional investors have recently bought and sold shares of the company. Gratus Capital LLC boosted its position in Thermo Fisher Scientific by 3.5% in the fourth quarter. Gratus Capital LLC now owns 18,661 shares of the company’s stock valued at $2,647,000 after buying an additional 630 shares during the last quarter. Private Advisor Group LLC boosted its position in Thermo Fisher Scientific by 25.6% in the fourth quarter. Private Advisor Group LLC now owns 12,260 shares of the company’s stock valued at $1,739,000 after buying an additional 2,501 shares during the last quarter. Baxter Bros Inc. boosted its position in Thermo Fisher Scientific by 14.0% in the fourth quarter. Baxter Bros Inc. now owns 11,836 shares of the company’s stock valued at $1,679,000 after buying an additional 1,449 shares during the last quarter. Quantitative Investment Management LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $3,049,000. Finally, GAM Holding AG boosted its position in Thermo Fisher Scientific by 2.7% in the fourth quarter. GAM Holding AG now owns 68,204 shares of the company’s stock valued at $9,674,000 after buying an additional 1,810 shares during the last quarter.
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.